Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Diagnostics Partnering Terms and Agreements
Publication Date Feb 2015
Publisher CurrentPartnering
Product Type Report
Pages 3419
Single User License help $ 3495.00
Site User License help $ 5245.00
Corporate User License help $ 17495.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

"The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies.
This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering:
Companion Diagnostics
Imaging
CT
Endoscope
Molecular and nuclear
MRI
Ultrasound
X-ray
PET
SPECT
Angiography
Fluroscopy
Mammography
In vitro diagnostics
Molecular diagnostics
Prognostics
Theranostics
The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
 
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
 
The initial chapters of this report provide an orientation of diagnostics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in diagnostics dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms and big pharma and big biotech activities.
                            
Chapter 3 provides a review of the leading diagnostics deals since 2009. Deals are listed by headline value and signed by big pharm. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
 
Chapter 4 provides a comprehensive listing of the top 50 big pharma companies that have announced diagnsotic deals, with a brief summary followed by a comprehensive listing of diagnostics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
 
Chapter 5 provides a comprehensive listing of the top 50 big biotech companies that have announced diagnsotic deals, where diagnostic deals are announced with a brief summary, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
 
Chapter 6 provides a comprehensive and detailed review of diagnostics partnering deals signed and announced since January 2009, where a contract document is available in the public domain. The chapter is organized by cpmpany A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
 
Chapter 7 provides a comprehensive and detailed review of diagnostics partnering deals signed and announced since January 2009. The chapter is organized by specific diagnostics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
 
The report also includes numerous tables and figures that illustrate the trends and activities in diagnostics partnering and dealmaking since 2009.
 
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of diagnostics technologies and products.
 
Report scope
 
Diagnostics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding of the diagnostic trends and structure of deals entered into by leading companies worldwide.
 
Diagnostics Partnering Terms and Agreements includes:
 
Trends in diagnostic dealmaking in the biopharma industry since 2009
Analysis of diagnostic deal structure
Case studies of real-life diagnostic deals
Access to over 3,000 diagnostic deals
The leading diagnostic deals by value since 2009
Most active diagnostic dealmakers since 2009
The leading diagnostic partnering resources
 
In Diagnostics Partnering Terms and Agreements , the available contracts are listed by:
 
Headline value
Stage of development at signing
Deal component type
Specific therapy target
 
Each deal title links via Weblink to online deal records of actual diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners."

"Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in diagnostic dealmaking
 
2.1. Introduction
2.2. Diagnostic partnering over the years
2.3. Most active diagnostic dealmakers
2.4. Big pharma diagnostic dealmaking activity
2.5. Big biotech diagnostic dealmaking activity
2.6. Diagnostics partnering by deal type
2.7. Diagnostics partnering by stage of development
2.8. Diagnostics partnering by disease type
2.9. Diagnostics partnering by specific technology type
2.10. Average deal terms for diagnostics partnering
2.10.1 Diagnostic partnering headline values
2.10.2 Diagnostic deal upfront payments
2.10.3 Diagnostic deal milestone payments
2.10.4 Diagnostic royalty rates
2.11. The anatomy of diagnostic partnering
2.11.1. The anatomy of a diagnostic deal
2.11.1.a. Case study 1: TrovaGene – Columbia University – December 2011
2.11.1.b. Case study 2: Neogenomics – Health Discovery – January 2012
2.11.1.c. Case study 3: Eli Lilly – Corgenix Medical – 2014
 
Chapter 3 – Leading diagnostic deals
 
3.1. Introduction
3.2. Top diagnostic deals by value
3.3. Top diagnostic deals involving big pharma
 
Chapter 4 – Big pharma diagnostic deals
 
4.1. Introduction
4.2. How to use big pharma diagnostic partnering deals
4.3. Big pharma diagnostic partnering company profiles
 
Chapter 5 – Big biotech diagnostics deals
 
5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech diagnostic partnering company profiles
 
Chapter 6 – Diagnostics contracts dealmaking directory
 
6.1. Introduction
6.2. By Company A-Z
6.3. By stage of development
6.4. By deal type
6.5. By therapy area
 
Chapter 7 – Diagnostics dealmaking by technology type
 
7.1. Introduction
7.2. Deals by diagnostics type
Chapter 8 – Diagnostic partnering resource center
 
8.1. Diagnostic partnering events
8.2. Further reading on diagnostic dealmaking
 
Recent report titles from Current Partnering
Order Form – Subscription Access Products
 
Appendices
 
Appendix 1: Diagnostics deals directory by Company A-Z 2009-2014
Appendix 2:  Diagnostics deals directory by deal type 2009-2014
Appendix 2:  Diagnostics deals directory by stage of development 2009-2014
Appendix 2:  Diagnostics deals directory by therapy type 2009-2014
 
Table of figures
 
Figure 1: Diagnostic partnering since 2009
Figure 2: Most active diagnostic dealmakers 2009-2014
Figure 3: Big pharma – top 50 – diagnostic deals 2009 to 2014
Figure 4: Big pharma diagnostic deal frequency – 2009 to 2014
Figure 5: Big biotech – top 50 – diagnostic deals 2009 to 2014
Figure 6: Big biotech diagnostic deal frequency – 2009 to 2014
Figure 7: Diagnostics partnering by deal type since 2009
Figure 8: Diagnostics partnering by stage of development since 2009
Figure 9: Diagnostics partnering by disease type since 2009
Figure 10: Diagnostics partnering by oncology target since 2009
Figure 11: Diagnostics partnering by diagnostics type since 2009
Figure 12: Diagnostics deals with a headline value by year- 2014
Figure 13: Diagnostics deals with a headline value by year- 2013
Figure 14: Diagnostics deals with a headline value by year- 2012
Figure 15: Diagnostics deals with a headline value by year- 2011
Figure 16: Diagnostics deals with a headline value by year- 2010
Figure 17: Summary median headline value by year, 2009-2014
Figure 18: Diagnostics deals with an upfront value by year- 2014
Figure 19: Diagnostics deals with an upfront value by year- 2013
Figure 20: Diagnostics deals with an upfront value by year- 2012
Figure 21: Diagnostics deals with an upfront value by year- 2011
Figure 22: Diagnostics deals with an upfront value by year- 2010
Figure 23: Diagnostics deals with an upfront value by year- 2009
Figure 24: Summary median upfront value by year, 2009-2014
Figure 25: Diagnostics deals with a milestone value by year- 2014
Figure 26: Diagnostics deals with a milestone value by year- 2013
Figure 27: Diagnostics deals with a milestone value by year- 2012
Figure 28: Diagnostics deals with a milestone value by year- 2011
Figure 29: Diagnostics deals with a milestone value by year- 2010
Figure 30: Diagnostics deals with a milestone value by year- 2009
Figure 31: Diagnostics deals with a royalty rate value by year- 2014
Figure 32: Diagnostics deals with a royalty rate value by year- 2013
Figure 33: Diagnostics deals with a royalty rate value by year- 2012
Figure 34: Diagnostics deals with a royalty rate value by year- 2011
Figure 35: Diagnostics deals with a royalty rate value by year- 2010
Figure 36: Diagnostics deals with a royalty rate value by year- 2009
Figure 37: Summary median royalty rate by year, 2009-2014
Figure 38: Components of the typical diagnostic deal structure
Figure 39: Top diagnostic deals by value since 2009
Figure 40: Top diagnostic deals signed by big pharma value since 2009
Figure 41: Forthcoming partnering events"

Title Date Price
2013 Deep Research Report on China Human Use Rabies Vaccine Industry
By QYResearch
2013 Deep Research Report on China Human Use Rabie Vaccine Industry is a professional and depth research report on China Human Use Rabies Vaccine industry. This report has firstly introduced Human Use ...Read More
Jan 2013 $2000.00
Abdominal Obesity-Pipeline Insights, 2014
By Delveinsight
SUMMARYDelveInsight’s,“ Abdominal Obesity-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establ ...Read More
$1250.00
Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed ...Read More
$2000.00
Abortion-API Insights, 2014
By Delveinsight
SummaryThe active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large numb ...Read More
$1250.00
Abscess- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Abscess- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed ...Read More
$2000.00
Abscess-API Insights, 2014
By Delveinsight
SummaryThe active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large numb ...Read More
$1250.00
Abscess-Pipeline Insights, 2014
By Delveinsight
SUMMARYDelveInsight’s,“ Abscess-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the un ...Read More
$1250.00
Absence Seizure- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Absence Seizure- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and m ...Read More
$2000.00
Absence Seizure-API Insights, 2014
By Delveinsight
SummaryThe active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large numb ...Read More
$1250.00
Acid Indigestion / Heartburn/ Pyrosis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Acid Indigestion / Heartburn/ Pyrosis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase II ...Read More
$2000.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

   
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9893555190
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z